- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00740610
Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 2, randomized, double-blind, parallel group, placebo controlled, multicenter study investigating the safety, tolerability, pharmacokinetics and activity of multiple oral doses of GS 9450 in adults with NASH. Approximately 110 subjects 18 75 years of age with elevated ALT (> 60 U/L at screening), fatty liver on screening ultrasound, and biopsy-proven NASH will be randomized (1:1:1:1:1) to one of five parallel treatment groups (22 subjects per treatment group) as follows:
GS-9450 1mg by mouth (PO) once daily, GS-9450 5 mg PO once daily, GS-9450 10 mg PO once daily, GS-9450 40 mg PO once daily, or Matching placebo PO once daily Qualifying subjects will be stratified by the presence/absence of type 2 diabetes (i.e., on/off oral diabetic medication at entry) and by geographic region (US and France). Following randomization, subjects will return within five business days later for a baseline visit, at which time they will be dispensed study medication and enter a 4-week treatment phase. Upon completion of the treatment phase, subjects will enter a 4 week off-treatment follow-up period. Each subject's participation in the study will last up to approximately 12 weeks (inclusive of screening, treatment phase, and off-treatment follow-up period).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75020
-
Vandoeuvre les Nancy, France, 54511
-
-
-
-
Arizona
-
Tucson, Arizona, United States
-
-
California
-
Fresno, California, United States
-
Fullerton, California, United States
-
San Diego, California, United States, 92161
-
San Mateo, California, United States
-
-
Colorado
-
Lakewood, Colorado, United States
-
-
District of Columbia
-
Washington, District of Columbia, United States
-
-
Florida
-
Jacksonville, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
-
Marietta, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Iowa
-
Des Moines, Iowa, United States
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
-
-
Louisiana
-
Monroe, Louisiana, United States
-
New Orleans, Louisiana, United States
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
-
Troy, Michigan, United States
-
-
New York
-
New York, New York, United States
-
Plainview, New York, United States
-
Syracuse, New York, United States
-
-
North Carolina
-
Asheville, North Carolina, United States
-
Durham, North Carolina, United States
-
Raleigh, North Carolina, United States
-
-
Ohio
-
Clevleand, Ohio, United States
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02905
-
-
Texas
-
Dallas, Texas, United States, 75203
-
Galveston, Texas, United States, 77555
-
Irving, Texas, United States
-
-
Virginia
-
Charlottesville, Virginia, United States
-
Falls Church, Virginia, United States
-
Richmond, Virginia, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-75 years of age
- ALT > 60 U/L
- fatty liver on screening ultrasound
- and biopsy-confirmed NASH
- platelet count >/= 75,000/mm3 and adequate hematologic function (absolute neutrophil count >/= 1,500/mm3, hemoglobin >/= 11.0 g/dL)
- calculated creatinine clearance >/= 70 mL/min
- non-insulin dependent diabetes for < 10 years is allowed if stably managed for at least 6 months prior to screening
- stable weight (no weight loss > 4%) for 8 weeks prior to screening and should maintain consistent diet, food intake, and physical exercise during the study
- must have been on stable therapy for at least 3 months prior to screening if receiving 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors, niacin, fibrates, vitamin E or angiotensin receptor blockers
- must have been on a stable treatment regimen for at least 3 months prior to screening if receiving other drugs possibly associated with hepatic adverse events (e.g., isoniazid, itraconazole, ketoconazole, rifabutin, rifampin, and other agents with significant hepatotoxic potential)
Exclusion Criteria:
- Insulin dependent diabetes mellitus, treatment with sulfonylureas (may be allowed pending results from a drug-drug interaction study), subjects receiving glitazones at screening or within 6 months of screening, presence of diabetic peripheral neuropathy or gastroparesis
- A > 4% decrease in weight within 8 weeks of screening
- cirrhosis or decompensated liver disease (defined as conjugated bilirubin > 1.5 x the upper limit of the normal range (ULN), prothrombin time > 1.5 x ULN, serum albumin < 3.0 g/dL, or prior history of clinical hepatic decompensation
- presence of other form of liver disease other than NASH
- history of excess alcohol ingestion, averaging > 3 drinks/day in the previous 2 years; or current alcohol intake averaging > 2 drinks/day for females and > 3 drinks per day for males; history of or current binge drinking
- serological evidence of co-infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV
- evidence of hepatocellular carcinoma (i.e., α-fetoprotein > 50 ng/mL)
- history of ingesting drugs possibly associated with hepatic steatosis within the past year
- history of total parenteral nutrition within the past 6 months
- prior history of gastroplasty, jejunoileal, or jejunocolonic bypass surgery
- history of ingesting drugs within the past 3 months that may improve NASH and associated fibrosis
- significant gastrointestinal disease that would interfere with absorption of oral medications; inflammatory bowel disease
- major surgery within the past year
- clinically significant abnormalities on ECG or other ECG findings that the investigator considers a safety risk
- significant systemic or major illnesses other than liver disease that, in the opinion of the investigator, would preclude treatment and adequate follow up
- prior or current malignancy involving any organ system and skin cancer (previously excised basal cell carcinoma allowed)
- acute ongoing infection, or symptoms of infection
- pregnant or breastfeeding females
- acute substance abuse within the past year.
- history of ingesting anti-TNFα drugs or immunomodulators within the past 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort 1
22 subjects to receive 1 mg GS-9450 for 4 weeks
|
GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
|
EXPERIMENTAL: Cohort 2
22 subjects to receive 5 mg GS-9450 for 4 weeks
|
GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
|
EXPERIMENTAL: Cohort 3
22 subjects to receive 10 mg GS-9450 for 4 weeks
|
GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
|
EXPERIMENTAL: Cohort 4
22 subjects to receive 40 mg GS-9450 for 4 weeks
|
GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
|
PLACEBO_COMPARATOR: Cohort 5
22 subjects to receive placebo to match GS-9450 for 4 weeks
|
Placebo to match GS-9450 administered orally once daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of Participants Who Experienced Adverse Events (AEs) and Graded Laboratory Abnormalities
Time Frame: Baseline to Post-treatment Week 24
|
Baseline to Post-treatment Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of GS-9450 and its metabolites
Time Frame: Weeks 2 and 4
|
Pharmacokinetics (Cmax, Tmax, Cmin, λz, t1/2, AUCtau, Vdss/F, and CL/F) measured by plasma sampling
|
Weeks 2 and 4
|
Change from baseline in alanine aminotransferase (ALT)
Time Frame: Baseline to Week 4
|
Baseline to Week 4
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GS-US-228-0101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Steatohepatitis
-
Duke UniversityCompletedLiver Diseases | Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | Nonalcoholic Fatty LiverUnited States
-
Gilead SciencesCompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States, New Zealand
-
National Institute of Diabetes and Digestive and...CompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States
-
Polaris GroupRecruiting
-
Corcept TherapeuticsRecruitingNonalcoholic Steatohepatitis (NASH)United States
-
PerspectumRecruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Metacrine, Inc.Completed
-
Cascade Pharmaceuticals, IncLaboratory Corporation of AmericaCompletedNonalcoholic Steatohepatitis (NASH)United States
-
Poxel SACompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
RWTH Aachen UniversityCompletedNASH - Nonalcoholic SteatohepatitisSweden, Austria, Germany
Clinical Trials on GS-9450
-
Gilead SciencesCompletedHCV InfectionUnited States, Netherlands, Germany
-
Gilead SciencesTerminatedHCV InfectionUnited States, United Kingdom, Germany, Canada, Puerto Rico, Poland
-
Gilead SciencesActive, not recruitingChronic Hepatitis BTaiwan, New Zealand
-
Gilead SciencesCompletedGenital WartsUnited States
-
Gilead SciencesOno Pharmaceutical Co. Ltd; Galapagos NVCompletedSjogren's SyndromeUnited States, Spain, United Kingdom, Poland
-
Gilead SciencesCompletedHepatitis C Virus InfectionUnited States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
-
Gilead SciencesCompletedHepatitis C Virus InfectionUnited States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
-
National Institute of Allergy and Infectious Diseases...Completed
-
Gesynta Pharma ABCTC Clinical Trial Consultants AB; RISE Research Institutes of Sweden ABCompleted
-
Gilead SciencesCompleted